Trabectedin for the therapy of ovarian cancer.

Antineoplastic Combined Chemotherapy Protocols Clinical Trials as Topic Dioxoles / adverse effects Female Humans Neoplasm Recurrence, Local / drug therapy Ovarian Neoplasms / drug therapy Tetrahydroisoquinolines / adverse effects Trabectedin
BRCA-mutated ovarian cancer DNA-damaging drugs Homologous recombination IL-6 production inhibitors Ovarian cancer therapy Trabectedin Tumor microenviroment

Journal

Drugs of today (Barcelona, Spain : 1998)
ISSN: 1699-3993
Titre abrégé: Drugs Today (Barc)
Pays: Spain
ID NLM: 101160518

Informations de publication

Date de publication:
Oct 2020
Historique:
entrez: 13 11 2020
pubmed: 14 11 2020
medline: 15 12 2020
Statut: ppublish

Résumé

Trabectedin is a marine-derivate antitumor drug with a relevant cytotoxic activity and good safety profile. It has been investigated for the treatment of solid diseases, including ovarian cancer (OC), breast cancer, and soft-tissue sarcoma. In 2009, results from the pivotal trial OVA-301 led the European Medicines Agency (EMA) to the approval of trabectedin in combination with PEGylated liposomal doxorubicin for the treatment of platinum-sensitive recurrent OC; further studies revealed an additional benefit also in the subgroup of patients with partially platinum-sensitive disease and in those with a BRCA-mutated status. Additionally, trabectedin demonstrated to prolong the time interval to the subsequent chemotherapy line. Recently, the improved understanding of the antitumor action exerted by trabectedin paved the way to new investigational trials exploring its combination with targeted therapies.

Identifiants

DOI: 10.1358/dot.2020.56.10.3187001 PMID: 33185631
pubmed: 33185631
pii: 3187001
doi: 10.1358/dot.2020.56.10.3187001
doi:

Substances chimiques

Dioxoles 0
Tetrahydroisoquinolines 0
Trabectedin ID0YZQ2TCP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

669-688

Informations de copyright

Copyright 2020 Clarivate Analytics.

Auteurs

G Evangelisti (G)

Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.

F Barra (F)

Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy. fabio.barra@icloud.com.

G D'Alessandro (G)

Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.

M Tantari (M)

Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.

S Stigliani (S)

Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.

L Della Corte (L)

Department of Neurosciences and Reproductive Sciences, School of Medicine, University of Naples Federico II, Naples, Italy.

G Bifulco (G)

Department of Neurosciences and Reproductive Sciences, School of Medicine, University of Naples Federico II, Naples, Italy.

S Ferrero (S)

Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Trabectedin for the therapy of ovarian cancer.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études cliniques comme sujet › Essais cliniques comme sujet › Trabectedin for the therapy of ovarian cancer.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Dioxoles › Trabectedin for the therapy of ovarian cancer.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Trabectedin for the therapy of ovarian cancer.
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Récidive tumorale locale › Trabectedin for the therapy of ovarian cancer.
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Trabectedin for the therapy of ovarian cancer.
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Isoquinoléines › Tétrahydroisoquinoléines › Trabectedin for the therapy of ovarian cancer.
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Isoquinoléines › Tétrahydroisoquinoléines › Trabectédine › Trabectedin for the therapy of ovarian cancer.